bullish

Remegen

Smartkarma Corporate Webinar | RemeGen: An Undervalued, Leading Biotech From China

4.8k Views27 Aug 2024 18:05
Boomeranged on Wed, 18 Sep 2024 15:01
RemeGen (9995 HK) is a leading biotech company committed to the discovery, development, and commercialization of innovative biologic drugs. Learn more about the company's impressive journey and future growth outlook within the biotech space in an engaging Smartkarma webinar, featuring RemeGen's CFO, Mr. Tong Shaojing and Smartkarma Insight Provider, Eric Wen.
SUMMARY

For our next Corporate Webinar, we are glad to welcome RemeGen's Chief Financial Officer, Mr. Tong Shaojing.

In the upcoming webinar, Tong will share a short company presentation after which, he will engage in a fireside chat with Smartkarma Insight Provider, Eric Wen . The Corporate Webinar will include a live Q&A session.

The Corporate Webinar will be hosted on Thursday, 19 September 2024, 09:00 SGT.

About RemeGen

RemeGen was cofounded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, a leading traditional Chinese medicine company in China and Dr. Fang Jianmin, a Canadian-American scientist. Headquartered in the coastal city of Yantai Shandong Province of China, RemeGen has research labs and offices throughout China and the United States. RemeGen is committed to the discovery, development, and commercialization of innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune oncology and ophthalmic diseases.

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
Logo
Smartkarma Research
Smartkarma Research Team
Smartkarma
Multi-Asset
Price Chart(Sign Up to Access)
analytics-chart
  • Smartkarma Corporate Webinar | RemeGen: An Undervalued, Leading Biotech From China
    27 Aug 2024
x